Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
John M. Kirkwood, Lars Bastholt, Caroline Robert, et al.
Clinical Cancer Research (2011) Vol. 18, Iss. 2, pp. 555-567
Open Access | Times Cited: 269

Showing 1-25 of 269 citing articles:

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty, Caroline Robert, Peter Hersey, et al.
New England Journal of Medicine (2012) Vol. 367, Iss. 2, pp. 107-114
Open Access | Times Cited: 2072
Targeting RAS–ERK signalling in cancer: promises and challenges
Ahmed A. Samatar, Poulikos I. Poulikakos
Nature Reviews Drug Discovery (2014) Vol. 13, Iss. 12, pp. 928-942
Closed Access | Times Cited: 1006
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Alan L. Ho, Ravinder K. Grewal, Rébecca Leboeuf, et al.
New England Journal of Medicine (2013) Vol. 368, Iss. 7, pp. 623-632
Open Access | Times Cited: 759
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto, Dirk Schadendorf, Carola Berking, et al.
The Lancet Oncology (2013) Vol. 14, Iss. 3, pp. 249-256
Closed Access | Times Cited: 620
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito, Christine A. Pratilas, Eric W. Joseph, et al.
Cancer Cell (2012) Vol. 22, Iss. 5, pp. 668-682
Open Access | Times Cited: 533
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante, et al.
The Lancet Oncology (2012) Vol. 13, Iss. 8, pp. 782-789
Open Access | Times Cited: 524
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Eli L. Diamond, Benjamin H. Durham, Julien Haroche, et al.
Cancer Discovery (2015) Vol. 6, Iss. 2, pp. 154-165
Open Access | Times Cited: 462
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kevin B. Kim, Richard Kefford, Anna C. Pavlick, et al.
Journal of Clinical Oncology (2012) Vol. 31, Iss. 4, pp. 482-489
Open Access | Times Cited: 446
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 4, pp. 435-445
Closed Access | Times Cited: 433
The clinical development of MEK inhibitors
Yujie Zhao, Alex A. Adjei
Nature Reviews Clinical Oncology (2014) Vol. 11, Iss. 7, pp. 385-400
Closed Access | Times Cited: 377
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Lawrence N. Kwong, James C. Costello, Huiyun Liu, et al.
Nature Medicine (2012) Vol. 18, Iss. 10, pp. 1503-1510
Open Access | Times Cited: 356
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
Anuradha Banerjee, Regina I. Jakacki, Arzu Onar‐Thomas, et al.
Neuro-Oncology (2017) Vol. 19, Iss. 8, pp. 1135-1144
Open Access | Times Cited: 277
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Murugan Kalimutho, Kate Parsons, Deepak Mittal, et al.
Trends in Pharmacological Sciences (2015) Vol. 36, Iss. 12, pp. 822-846
Closed Access | Times Cited: 274
MEK and the inhibitors: from bench to bedside
Akintunde Akinleye, Muhammad Furqan, Nikhil Mukhi, et al.
Journal of Hematology & Oncology (2013) Vol. 6, Iss. 1
Open Access | Times Cited: 270
MEK in cancer and cancer therapy
Cindy Neuzillet, Annemilaï Tijeras‐Raballand, Louis de Mestier, et al.
Pharmacology & Therapeutics (2013) Vol. 141, Iss. 2, pp. 160-171
Closed Access | Times Cited: 245
Systemic treatments for metastatic cutaneous melanoma
Sandro Pasquali, Andreas V. Hadjinicolaou, Vanna Chiarion‐Sileni, et al.
Cochrane library (2018) Vol. 2020, Iss. 11
Open Access | Times Cited: 220
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
Carolyn D. Britten
Cancer Chemotherapy and Pharmacology (2013) Vol. 71, Iss. 6, pp. 1395-1409
Closed Access | Times Cited: 209
ERKs in Cancer: Friends or Foes?
Xavier Deschênes‐Simard, Filippos Kottakis, Sylvain Meloche, et al.
Cancer Research (2014) Vol. 74, Iss. 2, pp. 412-419
Open Access | Times Cited: 203
Molecular Markers and Targets in Melanoma
Cristina Teixidó, Paola Castillo, Clara Martínez-Vila, et al.
Cells (2021) Vol. 10, Iss. 9, pp. 2320-2320
Open Access | Times Cited: 144
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations
Xu Chen, Qiong Wu, Lawrence Tan, et al.
Oncogene (2013) Vol. 33, Iss. 39, pp. 4724-4734
Open Access | Times Cited: 188
Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma
Geoffrey T. Gibney, Jane L. Messina, Inna V. Fedorenko, et al.
Nature Reviews Clinical Oncology (2013) Vol. 10, Iss. 7, pp. 390-399
Open Access | Times Cited: 178
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
Caroline Robert, Reinhard Dummer, Ralf Gutzmer, et al.
The Lancet Oncology (2013) Vol. 14, Iss. 8, pp. 733-740
Closed Access | Times Cited: 162
Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies, Georgina V. Long
Clinical Cancer Research (2014) Vol. 20, Iss. 8, pp. 2035-2043
Open Access | Times Cited: 147
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma
Su Yin Lim, Alexander M. Menzies, Helen Rizos
Cancer (2017) Vol. 123, Iss. S11, pp. 2118-2129
Open Access | Times Cited: 143
<em>NRAS</em>-mutant melanoma: current challenges and future prospect
Eva Muñoz‐Couselo, Esther Zamora, Carolina Ortiz, et al.
OncoTargets and Therapy (2017) Vol. Volume 10, pp. 3941-3947
Open Access | Times Cited: 141
Page 1 - Next Page

Scroll to top